Youth Suicide Prevention: CAMS-BI vs. Safety Planning in a Randomized Trial
Innovating Suicide Preventative Care for Youth; A Randomized Trial of CAMS- BI Versus Stanley- Brown Safety Planning Intervention in Preventing Suicide Driven Readmission
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 12 Years to 17 Years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
- Time periods mentioned: 90 days
Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.
Show the study's own words
- "Following the intervention, participants will be monitored for 90 days post-discharge, with follow-ups at 30, 60, and 90 days."
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
In plain language
This study compares two one-session treatments to help prevent suicide: CAMS-BI and safety planning. It is for teens ages 12–17 who are in a mental health hospital for suicidal thoughts or a suicide attempt. The study tracks suicidal thoughts and hospital or emergency room visits for 90 days after teens leave the hospital.
This study outlines a randomized controlled trial evaluating two brief suicide-specific interventions for adolescents aged 12-17 who are hospitalized for suicidal ideation or attempts. Suicide remains a leading cause of death among youth, and many adolescents are discharged from inpatient care without targeted, suicide-focused treatment, contributing to high rates of readmission and ongoing risk. This study seeks to address that gap by comparing the effectiveness of the Collaborative Assessment and Management of Suicidality-Brief Intervention (CAMS-BI) with the Stanley-Brown Safety Planning Intervention (SPI), both delivered as single-session interventions during inpatient hospitalization. Participants (N=118) will be randomly assigned to receive either CAMS-BI or SPI. CAMS-BI is a therapeutic, collaborative framework that focuses on identifying and addressing the underlying psychological drivers of suicidality, while SPI is a structured, practical approach that emphasizes immediate safety through coping strategies, support systems, and means restriction. Following the intervention, participants will be monitored for 90 days post-discharge, with follow-ups at 30, 60, and 90 days. The primary outcome is the rate of psychiatric readmissions and suicide-related emergency department visits within 90 days of discharge. Secondary outcomes include changes in suicidal ideation, measured by the Beck Scale for Suicide Ideation, and caregiver confidence in managing their child's safety. Additional measures include distress levels, hopelessness, treatment satisfaction, and engagement. The study hypothesizes that CAMS-BI will result in lower readmission rates, greater reductions in suicidal ideation, and improved caregiver confidence compared to SPI. Both interventions produce individualized safety or stabilization plans that are shared with patients and caregivers and incorporated into discharge planning to support continuity of care. Safety protocols are emphasized throughout the study, given the high-risk population. Participants receive standard clinical care, crisis resources, and close monitoring, with procedures in place to address any escalation in suicide risk. Data will be collected using secure systems, and confidentiality will be maintained through de-identification and controlled access. Overall, this study aims to determine whether a rapid, inpatient, suicide-focused intervention can improve short-term outcomes for high-risk youth and reduce the likelihood of rehospitalization, ultimately informing scalable approaches to suicide prevention in clinical settings.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Who can join
- Age 12–17.
- In a mental health hospital because of a suicide attempt or current suicidal thoughts.
- Both the teen and parent or guardian speak English.
- The teen can understand and is willing to sign a study agreement. A parent or guardian must also be willing and able to sign a consent form.
Who can't join
- Moderate or severe intellectual disability, described as an IQ below 70 and being in special education classes full time.
- Schizophrenia or any past psychosis, which means losing touch with reality. This includes psychosis linked to mood problems or a brief episode.
- In the custody of Children's Services.
Simplified for readability. The official criteria below are what the study team uses.
Official eligibility criteria
Inclusion Criteria: * Adolescents aged 12-17 years. * Admitted to inpatient psychiatry for suicide attempt or active suicidal ideation. * English-speaking patient and parent/guardian. * Ability to understand and the willingness to sign a written informed assent document with a parent/guardian willing and able to sign a written informed consent. Exclusion Criteria: * Moderate or severe intellectual disability (IQ less than 70 and those patients in special education classes full time). * Schizophrenia or history of any type of psychosis including mood related psychosis and brief reactive psychosis. * In custody of Children's Services.
Study sites (1)
OH
- The Cleveland Clinic · Cleveland, OH 44195Tatiana Falcone, M.D. · Study contact · (216) 444-7459 · falcont1@ccf.orgMore trials in Cleveland